Long-term, continuous dosing of etanercept in patients with plaque psoriasis

References

• Ashcroft DM, Wan Po AL, Williams HC, Griffiths CEM. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br. J. Dermatol.141, 185–191 (1999).
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J. Am. Acad. Dermatol.58, 826–850 (2008).
   PubMed Web of Science ®Google Scholar
• Pathirana D, Ormerod AD, Saiag P et al. Guidelines: European S3-Guidelines on the systemic treatment of psoriasis vulgaris. J. Eur. Acad. Dermatol. Venereol.23(Suppl. 2), 5–70 (2009).
   Web of Science ®Google Scholar
• Bonifati C, Carducci M, Cardiali Fei P et al. Correlated increases of tumour necrosis factor-α, interleukin-6 and granulocyte monocyte-colony stimuating factor levels in suction blister fluids and sera of psoriatic patients-relationships with disease activity. Clin. Exp. Dermatol.19, 383–387 (1994).
   PubMed Web of Science ®Google Scholar
• Ettehadi P, Greaves MV, Wallach D et al. Elevated tumour necrosis factor-α (TNF-α) biological activity in psoriatic skin lesions. Clin. Exp. Immunol.96, 146–151 (1994).
   PubMed Web of Science ®Google Scholar
• Bonifati C, Ameglio F. Cytokines in psoriasis. Int. J. Dermotol.38, 241–251 (1999).
   PubMed Web of Science ®Google Scholar
• Ortonne J-P, Griffiths CEM, Daudén E et al. Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study. Exp. Rev. Dermatol.3, 657–665 (2008).
   Google Scholar
• Leonardi C, Strober B, Gottlieb AB et al. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J. Drugs. Dermatol.9, 928–937 (2010).
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med.349, 2014–2022 (2003).
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M et al. A global Phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol.152, 1304–1312 (2005).
   PubMed Web of Science ®Google Scholar
• Tyring S, Gordon KB, Poulin Y et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch. Dermatol.143, 719–726 (2007).
   PubMed Web of Science ®Google Scholar
• Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J. Am. Acad. Dermatol.51, 563–569 (2004).
   PubMed Web of Science ®Google Scholar
• Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann. Rheum. Dis.64(Suppl. 2), ii65–ii73 (2005).
   PubMed Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin. Exp. Dermatol.19, 210–216 (1994).
   PubMed Web of Science ®Google Scholar
• Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a Phase II study. Health Qual Life Outcomes.4, 71 (2006).
   PubMed Web of Science ®Google Scholar
• Heron M, Tejada-Vera B. Deaths: leading causes for 2005. Natl. Vital Stat Rep.58, 1–97 (2009).
   PubMedGoogle Scholar
• Harris RB, Griffith K, Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985–1996. J. Am. Acad. Dermatol.45, 528–536 (2001).
   PubMed Web of Science ®Google Scholar
• Gray DT, Suman VJ, Su WPD, Clay RP, Harmsen WS, Roenigk RK. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch. Dermatol.133, 735–740 (1997).
   PubMed Web of Science ®Google Scholar
• Morsy H, Kamp S, Jemec GBE. Outcomes in randomised controlled trials in psoriasis: what has changed over the last 20 years? J. Dermatolog. Treat.18, 261–267 (2007).
   Web of Science ®Google Scholar
• Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI50) is a clinically significant endpoint in the assessment of psoriasis. J. Am. Acad. Dermatol.50, 859–866 (2004).
   PubMed Web of Science ®Google Scholar
• Papp KA, Poulin Y, Bissonnette R et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J. Am. Acad. Dermatol. DOI: 10.1016/j.jaad.2010.07.026 (2010) (Epub ahead of print).
   Google Scholar
• Driessen RJB, Boezeman JB, van de Kerkhof PCM, de Jong EMGJ. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br. J. Derm.160, 67–75 (2009).
   Google Scholar
• Zaragoza V, Perez A, Sanchez JL, Oliver V, Martinez L, Alegre V. Long-term safety and efficacy of etanercept in the treatment of psoriasis. Acta Dermasifiliogr.101, 47–53 (2010).
   Google Scholar
• Esposito M, Giunta A, Mazzotta A et al. Continuous treatment of plaque-type psoriasis with etanercept: an observational long-term experience. Int. J. Immunopathol. Pharmacol.23, 503–509 (2010).
   Google Scholar